Physician

Anmol Singh, M.D.

According to 2025 Medicare claims, Anmol Singh, M.D. (NPI: 1720510100) practices hematology/oncology in the Arlington-Alexandria-Reston, VA-WV market, with the plurality of this provider's patient population coming from Prince William, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER SPECIALISTS, P.C. (NPI: 1346294519; TIN: 541795091) and primary practice location at 20110-9998. Singh is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 480 traditional Medicare patients, billed 117,539 HCPCS/CPT codes, and received $2,454,514 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 336 prescription claims across 68 beneficiaries totaling $390,296 in drug costs, led by Eliquis (Apixaban). DME data shows 12 claims. Open Payments data shows 89 records totaling $3,093. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have risen steadily, from $10,502 to $390,296. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	251	38,316	$849,783
2024	480	117,539	$2,454,514

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	46	124	$10,502
2018	57	214	$18,096
2019	56	297	$11,217
2020	38	130	$9,454
2021	N/R	11	$18,113
2022	15	36	$27,584
2023	22	93	$37,851
2024	68	336	$390,296

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$275

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	103	253	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	102	215	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	128	173	$62
36415	Insertion of needle into vein for collection of blood sample	109	275	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	105	272	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	29	1,082	$20,431
Anastrozole	Anastrozole	66	3,563	$485
Prochlorperazine Maleate	Prochlorperazine Maleate	29	208	$334
Dexamethasone	Dexamethasone	27	160	$300
Gabapentin	Gabapentin	18	720	$155

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
K0003	Lightweight wheelchair	Y	N/R	12	$275

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	89	$3,093	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anmol Singh, M.D.?

Tedicare shows public-source Medicare data for Anmol Singh, M.D. (NPI 1720510100), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anmol Singh, M.D. have ACO affiliation data?

Anmol Singh, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Anmol Singh, M.D.?

Anmol Singh, M.D. is linked to VIRGINIA CANCER SPECIALISTS, P.C. (billing NPI 1346294519) in the available physician profile data.

Does Anmol Singh, M.D. have Open Payments data?

Anmol Singh, M.D. has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.